Quick Update for Elanco Animal Health (ELAN) Investors

Shares of Health Care sector company Elanco Animal Health moved 14.3% today, and are now trading at a price of $10.7. The mid-cap stock's daily volume was 13,477,819 compared to its average volume of 5,007,064. The S&P 500 index returned a 0.0% performance.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. The company is based in Greenfield and has 9,000 full time employees. Its market capitalization is $5,271,632,896.

8 analysts are following Elanco Animal Health and have set target prices ranging from $9.5 to $19.0 per share. On average, they have given the company a rating of hold. At today's prices, ELAN is trading -22.52% away from its average analyst target price of $13.81 per share.

Over the last year, ELAN shares have gone down by -19.0%, which represents a difference of -34.0% when compared to the S&P 500. The stock's 52 week high is $14.69 per share and its 52 week low is $7.88. Although Elanco Animal Health's average free cash flow over the last 6 years has been $154.8 Million, they have been decreasing at an average rate of -39.1%. For this reason, investors may continue to shun the stock.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 118,000 138,000 -20,000 -106.35
2022 452,000 137,000 315,000 -11.76
2021 483,000 126,000 357,000 323.12
2020 -41,000 119,000 -160,000 -290.48
2019 224,000 140,000 84,000 -76.19
2018 487,300 134,500 352,800
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

ON FOCUS